Cabozantinib improves PFS in metastatic renal cell carcinoma

Share :
Published: 10 Oct 2016
Views: 1945
Dr Toni Choueiri - Dana Farber Cancer Institute, Boston, USA

Dr Choueiri speaks with ecancertv at ESMO 2016 to discuss results from two trials for novel therapies against metastatic renal cell carcinoma (mRCC).

First, he discusses the comparative trial CABOSUN, investigating cabozantinib versus sunitinib, and then a phase 1b dose escalation of checkpoint inhibitor therapy in combination with axitinib.

Considering the results of these trials, Dr Choueiri describes his hopes for the future of mRCC care.

Video of the press conference in which the CABOSUN results were presented is available here, and details are available in the news coverage here.